

RESEARCH

Open Access

PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment

Carlo Cenciarelli^{1*}, Hany ES Marei², Manuela Zonfrillo¹, Pasquale Pierimarchi¹, Emanuela Paldino³, Patrizia Casalbone³, Armando Felsani³, Angelo Luigi Vescovi⁴, Giulio Maira⁵ and Annunziato Mangiola⁵

Abstract

Background: Cancer stem cells (CSC) represent a rare fraction of cancer cells characterized by resistance to chemotherapy and radiation, therefore nowadays there is great need to develop new targeted therapies for brain tumors and our study aim to target pivotal transmembrane receptors such as Notch, EGFR and PDGFR, which are already under investigation in clinical trials setting for the treatment of Glioblastoma Multiforme (GBM).

Methods: MTS assay was performed to evaluate cells response to pharmacological treatments. Quantitative RT-PCR and Western blots were performed to state the expression of Notch1, EGFR and PDGFR α/β and the biological effects exerted by either single or combined targeted therapy in GBM CSC. GBM CSC invasive ability was tested in vitro in absence or presence of Notch and/or EGFR signaling inhibitors.

Results: In this study, we investigated gene expression and function of Notch1, EGFR and PDGFR to determine their role among GBM tumor core- (c-CSC) vs. peritumor tissue-derived cancer stem cells (p-CSC) of six cases of GBM. Notch inhibition significantly impaired cell growth of c-CSC compared to p-CSC pools, with no effects observed in cell cycle distribution, apoptosis and cell invasion assays. Instead, anti-EGFR therapy induced cell cycle arrest, sometimes associated with apoptosis and reduction of cell invasiveness in GBM CSC. In two cases, c-CSC pools were more sensitive to simultaneous anti-Notch and anti-EGFR treatment than either therapy alone compared to p-CSC, which were mostly resistant to treatment. We reported the overexpression of PDGFR α and its up-regulation following anti-EGFR therapy in GBM p-CSC compared to c-CSC. RNA interference of PDGFR α significantly reduced cell proliferation rate of p-CSC, while its pharmacological inhibition with Crenolanib impaired survival of both CSC pools, whose effects in combination with EGFR inhibition were maximized.

Conclusions: We have used different drugs combination to identify the more effective therapeutic targets for GBM CSC, particularly against GBM peritumor tissue-derived CSC, which are mostly resistant to treatments. Overall, our results provide the rationale for simultaneous targeting of EGFR and PDGFR, which would be beneficial in the treatment of GBM.

Introduction

Glioblastoma multiforme (GBM) is an aggressive type of brain cancer that resists treatment. Recently, it has been established that in many types of cancer the bulk of cells that make up a tumor are derived from a small population of CSC, also known as tumor initiating cells. CSC are distinguished from the bulk of the population of

tumor cells by their ability to successfully seed new tumors when implanted in low numbers into experimental animals. Such cells are proposed to persist in recurrent GBM and to have enhanced resistance to chemotherapy and radiation-induced apoptosis [1].

The Notch pathway plays an important role in cellular processes during embryonic and postnatal development, including stem cells renewal, cell fate determination and apoptosis. A role for Notch signaling in the maintenance of cancer stem cells has been described in preclinical models and recently in clinical studies [2-4]. Increasing

* Correspondence: cencia65@gmail.com

¹Institute of Translational Pharmacology-CNR, Roma, Italy

Full list of author information is available at the end of the article

evidence demonstrates a deregulated expression of Notch receptors and Notch ligands in GBM, and their knockout inhibit gliomas proliferation and survival. Therefore this pathway could be considered as a therapeutic target for cancer therapy [5,6]. Notch receptor is synthesized as an inactive 300 kDa precursor protein, which is proteolytically cleaved by a furin-like convertase before it inserts as a non-covalently bound heterodimer in the plasma membrane. There are four Notch receptors (Notch1, 2, 3 and 4) and five ligands of the DSL (Delta and Serrate Ligands) family, which includes Delta-like ligands (DLL) 1, 2, 3, and Serrate/Jagged (JAG) 1 and 2. Members of both the Notch receptor and DSL ligand families are, for the most part, type I single-pass integral membrane proteins. Signaling is initiated by binding of a Notch ligand expressed on one cell to a Notch receptor on an adjacent cell. Upon ligand binding to the receptor, Notch is sequentially cleaved by ADAM10/TACE (a disintegrin and metalloproteinase) and by a presenilin-dependent γ -secretase protease complex which consists of presenilin 1 (PSEN1) or PSEN2, Nicastrin, PEN2 and APH1 [7]. This process results in the release in the cytoplasm of a soluble fragment consisting of the entire intracellular domain, termed Notch intracellular domain (NICD). After translocation to the nucleus, NICD binds to transcription factor CSL, and converts a large co-repressor in an active transcriptional complex that activates the transcription of Notch target genes. These include genes encoding Hairy Enhancer of Split (HES1), HES-related proteins (HEY), p21^{waf1}, Cyclin D1 and 3, c-myc, and HER2 [8-11].

A number of genetic alterations are responsible for the malignancy of GBM, often mutations leading to the hyperactivation of receptor tyrosine kinases (RTK). A combination of proteomic and genomic analyses of 243 GBM from The Cancer Genome Atlas (TCGA), subdivides these tumors into three subclasses based on the pattern of expression and genetic alterations: classical/EGFR+, proneural/PDGFR+ and mesenchymal/NF1+ classes [12]. Le Mercier et al. [13], report that the addition of temozolomide to conventional radiotherapy significantly improved the survival of patients belonging to the classical subtype, but it did not affect the survival of patients belonging to the proneural subtype, suggesting the importance to clinically subdividing patients in order to devise the best targeted therapy. EGFR is overexpressed in almost 40-50% of GBM and contributes to uncontrolled proliferation and survival of glioma cells [14]. A well-documented alteration in GBM is the amplification and activating mutation of EGFR variant III (EGFRvIII). EGFRvIII has an overall prevalence of almost 60% in patients whose tumors show amplification of wild type (wt) EGFR [15,16]. Enhanced activation of RTK leads to the activation of intracellular signaling pathways such as the Raf/MEK/Erk and the PI3K/Akt pathways, which are

ultimately responsible for the malignant phenotype of glioma cells [17].

Another subset of gliomas, the PDGFR subclass account for 25-30% of GBM, and is characterized by dysregulation of PDGFR activity, which in some cases is due to amplification and rearrangements of the PDGFR α gene locus, and in others to overexpression of the PDGF ligands [12,18,19]. PDGFR is a transmembrane receptor with 5 immunoglobulin-like repeats in its extracellular domain and a tyrosine kinase in its intracellular domain. There are four PDGF ligands (PDGF-A, PDGF-B, PDGF-C and PDGF-D) that dimerize and bind to PDGF receptors, PDGFR α and PDGFR β [20]. PDGF-A, PDGF-B, and PDGF-C bind to PDGFR α ; PDGF-B and PDGF-D bind to PDGFR β . The binding of a ligand to the receptor induces its autophosphorylation and activation of pivotal intracellular signals (MAP kinase, PI3K/Akt, JAK/STAT and PLC-PKC), which results in proliferation, survival, migration and oncogenesis [21]. Recently, Kim et al. [22] report that genetic or pharmacological targeting of PDGFR β in selected CD133 positive GBM CSC (but not PDGFR α), attenuated self-renewal, survival, tumor growth and invasion. Therefore, development of specific therapies using tyrosine kinase inhibitors (TKI) targeted toward CSC holds promise, but cancer cells may acquire resistance to TKI. In fact, it has been reported that EGFR-mutant glioblastomas may evade EGFR TKI by transcriptionally repressing PDGFR β [23].

The current study aims to devise strategies to selectively target pivotal plasma membrane receptors relevant to maintenance of either core tumor- (c-CSC) or peritumor tissue (p-CSC)-derived GBM cancer stem cells. We investigated the biological effects on these classes of CSC mediated by TKI targeting individually Notch1, EGFR and PDGFR signaling respectively. Combination therapy with EGFR and Notch inhibitors provided more significant therapeutic effects than single therapy alone, promoting in some cases more apoptosis in c-CSC than p-CSC. The combination of EGFR and PDGFR inhibitors sensitizes either the most resistant GBM p-CSC or c-CSC to apoptosis. This finding is highly relevant because the peripheral area of the tumor is the site of recurrent GBM in 90% of cases. The *in vitro* pharmacological studies on CSC are a such compelling model as they hold the potential to develop new therapeutic strategies before employing them in clinical trials.

Results


GBM CSC culture and evaluation of Notch1 and RTKs gene expression

Cancer stem cells from GBM were isolated using defined criteria set up by neurosurgeons as described previously [24,25]. We can summarize these briefly: lesion removal was achieved with resection margins that included the

tumor and the neighboring, apparently normal tissue (between 1-2 cm from the tumor border; larger resections were performed in tumors that grew far from eloquent areas), which were removed entirely en bloc. Neuronavigation and intraoperative ultrasound were used to maximize the extent of intracranial tumor resection. From this bulk we retrieved either core- (c-CSC) or peritumor tissue-derived cancer stem cells (p-CSC). Cytogenetic and molecular analysis showed that the two types of CSC have quite diverse tumorigenic potential and distinct genetic anomalies [24]. Neurospheres of different sizes were obtained from cores of multiple specimen of GBM patients; these continued to propagate in suspension in long-term culture. CSC derived from peritumor tissue of GBM at early passages exhibited a different phenotypic behavior compared to c-CSC: they grew at a slow rate, forming small spheres, most of them attached

to the plastic dishes. These latter particular morphological features, in some cases, were gradually lost at late passages in culture (data not shown).

To understand how Notch1 and epidermal growth factor receptor (EGFR) signaling would affect cell growth and survival of GBM CSC, we first assessed the mRNA expression profile in six human cases, consisting of paired samples of c-CSC and p-CSC, for a total number of twelve CSC. RT-PCR experiments for NOTCH1, HES1, EGFR wt and variant EGFRvIII, were performed in triplicate for each sample and the relative expression reported as $-\Delta Ct$ (Figure 1A-C). Notably, the p-CSC3 and p-CSC4 showed a significant up regulation of NOTCH1 gene compared to relative c-CSC, either at mRNAs level or the protein content of the Notch intracellular domain 1 NICD1, (the active form of Notch1) (Figure 1A, E). We carried out in parallel a custom RT-PCR array in the most studied cases



(cases 1-3), which revealed and confirmed the up modulation of Notch signaling components in p-CSC3 versus c-CSC3, expressed as fold change (Fc) and including: NOTCH3 (4.78 Fc), Nicastrin (NCSTN, 3.4 Fc), Presenilin1 (PSEN1, 2.39 Fc), Mastermind-like 1-2 (MAML1, MAML2, 2.36 and 3.24 Fc respectively), Delta-Like Ligand 1, (DLL1, 7.91 Fc), and Serrate Ligand Jagged2, (JAG2, 3.66 Fc) (Figure 1B, C). The high mRNA levels of HES1, a Notch1 primary target gene, directly correlated to those of Notch1 in p-CSC3 and p-CSC4, suggesting a Notch1 dependent mechanism for Hes1 gene regulation (Figure 1A, B). Conversely, the high levels of HES1 mRNA inversely correlated to Notch1 gene expression in p-CSC2 (Figure 1A, B), suggesting that other signals converged in case-2 for HES1 gene transcription. A custom RT-PCR array for genes encoding Notch signaling components confirmed the reduction of Notch1 activation in p-CSC2 as well as NICD1 protein expression as compared to c-CSC2 (Figure 1D, E). Hes1 protein was detected in all CSC, raising the possibility that further mechanisms may contribute to Hes1 protein stability through the sonic hedgehog pathway as well as post-translational processes [26,27].

The only mRNA positivity relative to EGFRvIII was found in c-CSC1, which represent around 16% of the specimens studied. EGFR mRNA expression was up modulated

in c-CSC1, 3 and 4, down modulated in c-CSC2 compared to relative counterparts, or unmodulated in the rest of the cases (Figure 1C). EGFR protein expression mirrored the levels of transcripts in the same samples. We extended our protein analysis to another RTK, the platelet derived growth factor receptor isoforms α and β (PDGFR α/β). The inherent over expression of PDGFR α in p-CSC pools suggests this as a molecular signature of the GBM peritumor tissues, while PDGFR β was expressed either in c-CSC or p-CSC of the six cases examined (although we have documented increasingly expression levels in p-CSC pools except for Case 6) (Figure 1E). We also reported the over expression of c-Myc, a direct target of Notch1 [10], which was equally express in all CSC.

Differential response of GBM CSC to treatment with GSI-X and AG1478

CSC undergoing treatment with γ -secretase inhibitor-X (GSI-X), a Notch signaling inhibitor, either alone or along with an EGFR signaling inhibitor AG1478, were evaluated for any changes in cellular response by MTS assay. Here, the experiments were conducted only on cases 1, 2 and 3 (Figure 2). c-CSC2 and c-CSC3 were significantly sensitized with 2 μ M of GSI-X after 3 days. Conversely, p-CSC2 showed an increase of cell proliferation, while p-CSC3 were not affected even at higher concentration of GSI-X




Figure 2 Differential response of the GBM CSC to GSI-X and AG1478 treatment. (A) GSI-X negatively affect cell proliferation of GBM c-CSC pools after 3 and 5 days of treatment as compared to p-CSC pools by MTS assay. (B) GBM CSC proliferation decrease after 2 days by single EGFR inhibition. Concurrent EGFR and Notch1 inhibition results in a synergistic anti-proliferative effect in c-CSC2 and c-CSC3 pools as compared to relative p-CSC pools. Error bars represent the mean \pm SD (n = 3). All data shown are representative of results obtained from experiments conducted three times.

(Additional file 1: Figure S1). In Case 1, both c-CSC1 and p-CSC1 showed resistance to the treatment after 3 days (Figure 3A); instead the treatment on the 5th day dropped proliferation of c-CSC1 to $70 \pm 4.6\%$ (Figure 2A). The treatment with $10 \mu\text{M}$ of AG1478 resulted in a significant sensitization of all six CSC as detected by MTS assay (Figure 2B).

No close correlation between sensitization to AG1478 with the levels or the mutational state of EGFR gene was found (Figure 1C, E). In fact, cell proliferation decreased to $28.3 \pm 6.1\%$ and $30.9 \pm 8.3\%$ in c-CSC1 and p-CSC1, respectively (Figure 2B), although c-CSC1 would overexpress both full-length and the variant III of EGFR (Figure 1E). In c-CSC2 and c-CSC3 cell proliferation dropped to $44.8 \pm 6.4\%$ and $49 \pm 2.1\%$ respectively against to $59.2 \pm 4.1\%$ of p-CSC2 and $65.2 \pm 5.5\%$ of p-CSC3. The treatment with the two inhibitors caused a synergistic anti-proliferative effect in c-CSC2 and c-CSC3, bringing cell proliferation down to $19 \pm 8.3\%$ and $34 \pm 3.8\%$ respectively (Figure 2B), while growth of p-CSC2 and p-CSC3 remained unmodified at $57 \pm 2.9\%$ and $70 \pm 5.6\%$, respectively. This finding argued for a stronger anti-Notch1 and EGFR resistance of p-CSC vs. c-CSC pools, at least in these 2 cases.

To substantiate the effects observed by MTS assay, we carried out Western blots analysis for the main signal molecules relevant for proliferation and cell survival

(Figure 3). The concentration of the inhibitors used in our treatment was effective in inhibiting Notch1 cleavage and EGFR phosphorylation on Try1068. Notably, only c-CSC1 showed a protein doublet of 180 and 140 kDa (corresponding to the full-length and EGFRvIII respectively); the rest of cases displayed the full length isoform (Figure 3). We evaluated the activation and modulation of the main downstream effectors of EGFR signaling, such as Akt1, Erk1/2 and Stat3, after two days of treatment. No significant changes of phosphorylation state of p-Akt1 and p-Erk1/2 were found in the three cases examined after 2 days of treatment with GSI-X. p-CSC3 displayed resistance even to higher concentration of GSI-X (Additional file 1: Figure S1). Conversely, p-Erk1/2 was suppressed in case 1, and significantly down modulated in case 2 and 3, except for p-CSC3, following AG1478 treatment. The combination of the two agents suppressed p-Erk1/2 expression in case 2 and 3, but it was still preserved in p-CSC3 and similarly results were seen for p-Akt-1 activation. Stat3 phosphorylation on Y705 has been shown to be directly mediated by EGFR or indirectly by proteins of JAK family. EGFR signaling inhibition caused a decrease of phosphorylation of p-Stat3 in case 2 and c-CSC3, conversely in p-CSC1 and p-CSC3 the levels of p-Stat3 were unmodulated, suggesting a mechanism of resistance to EGFR TKI treatment in these cases. PDGFR β was more expressed in p-CSC




Figure 3 Dual inhibition contributes to down modulation of PI3K/Akt, ERK1/2 and Jak/STAT3 pathways in GBM CSC. (A) Western blots in Case 1 reveal none modulation of Notch1 target Hes1 protein by GSI-X. EGFR inhibition affects the phosphorylation status either of the full-length or EGFRvIII. p-Akt1 (S473) and p-Erk1/2 (T202/Y204) disappear with the dual treatment in both of pools, but p-Stat3 (Y705) and PDGFR β expression was maintained high in p-CSC1 after treatment, and probably contribute to drug resistance. (B) Western blot analysis reveal no modulation of Notch1 target Hes1 protein in both pools of Case 2. Decrease of p-Akt1 protein levels by GSI-X in c-CSC2 but not in p-CSC2. Either p-Erk1/2 or p-Akt1 disappear following dual treatment. Higher levels of p-Stat3 in p-CSC2 compared to c-CSC2 may contribute to drug resistance as observed in p-CSC1. AG1478 alone or combined with GSI-X downmodulates the levels of p-Stat3 and PDGFR β . (C) Western blot analysis detects significant differences in NICD1, EGFR and PDGFR β protein expression between core- and p-CSC3. c-CSC3 show no modulation of p-Akt1 and p-Erk1/2 by Notch inhibition, while AG1478 causes p-Erk1/2 decrease but not p-Akt1. Dual treatment triggers a decrease of p-Stat3 with a significant loss of p-Akt1 in c-CSC3. On the contrary, p-CSC3 pool maintains an high expression of p-Akt1, p-Erk1/2, PDGFR β and p-Stat3 either after AG1478 or dual treatment, which may explain the high cell drug resistance. Arrows denote the doublet of EGFR full-length and EGFRvIII.

than in c-CSC pools and unmodulated by either GSI-X or AG1478 alone, except for CSC2 that showed PDGFR β down modulation by AG1478 treatment (Figure 3A-C).

Simultaneous GSI-X and AG1478 treatment trigger apoptosis in core-CSC

The main biological responses of cancer stem cells described in the literature following treatment with Notch inhibitors are: arrested cells and induction of apoptosis. Flow cytometry analyses showed a moderate apoptosis/necrosis induced by GSI-X, which resulted 4.7% and 12% in c-CSC2 and c-CSC3 respectively respect to 0.3% and 5% in DMSO-treated cells (Figure 4B, C). Single AG1478 treatment was more effective than GSI-X, as c-CSC2 and c-CSC3 were both shifted in G1 phase (61.8% and 82.1% respectively as compared to 54.2% and 74.5% in DMSO-treated cells) and induced to apoptosis/necrosis (9% and 10%, respectively).

Dual treatment raised apoptosis/necrosis to 10.2% in c-CSC2 and 27% in c-CSC3. These results were verified by induction of Caspase-3 and PARP-1 cleavage, reduction of both Survivin and Cyclin D1 as reported by Western blots (Figure 4B, C). AG1478 determined the accumulation of p-CSC2 in G1 phase (74.9%), while the dual treatment raised this to 78.7% compared to 61.3% in DMSO-treated cells. The slowing of cell cycle progression was associated with loss of Cyclin D1 and increase of p27^{Kip}, but we monitored very low levels of Caspase-3 and PARP-1 cleavage fragments, and no effect on Survivin protein levels. Conversely, p-CSC3 were fully resistant to treatment (Figure 4C). EGFR inhibition induced cell cycle arrest of both c-CSC1 and p-CSC1 which amounted to 84.3% and 87.9% respectively versus 66.2% and 58.1% in DMSO-treated cells. This finding correlated with high induction of p27^{Kip1} (Figure 4A). Cyclin D1 was not detected by Western blots, although mRNAs were monitored by custom RT-PCR array (data not shown).

Cell invasion properties of GBM CSC


In order to assess the invasion capabilities of CSC and the effects of the inhibitors either alone or in combination a matrigel invasion assay was performed. To invade the cells need an active process that involves cell motility and extracellular matrix proteolysis, and for this reason we monitored the expression of MMP-9, matrix metalloproteinase-9, which belongs to MMP family involved in tumor progression, including invasion and cancer metastasis [28]. Cell invasion ability was assessed in cases 1, 2 and 3 in absence or presence of growth factors (GF). In absence of GF, both p-CSC1 and p-CSC2 hold higher invasive ability compared to relative counterparts; conversely, c-CSC3 are much more invasive than p-CSC3. Following addition of GF, all CSC moved significantly through the plastic insert of the trans-wells

dishes (Figure 5A-C). GSI-X treatment did not affect the invasive ability of any CSC, except for c-CSC3, although other authors report that genetic Notch1 knockdown resulted in reduced cell migration invasion in a glioma cell line by inhibition of β -catenin and NF- κ B signaling [29].

It has been reported that EGFR inhibition efficiently blocked EGF-induced activation of MMP9 and cancer invasiveness [30]. In our work AG1478 treatment induced differential effects, in part explained by the RTK profile. AG1478 inhibited cell invasion and MMP9 protein expression in c-CSC1 and p-CSC1, whereas the combination therapy resulted in suppression of MMP-9 (Figure 5A). AG1478 alone did not affect the invasive ability of c-CSC2 and p-CSC2, but the dual treatment influenced significantly both pools of cells and directly correlated with a stronger reduction of MMP-9 in c-CSC2 than in p-CSC2 (Figure 5B). Similar outcomes were obtained in c-CSC3, and the influence of this combination treatment was superior to monotherapy with AG1478. Conversely, p-CSC3 had a modest invasion ability compared to c-CSC3, probably due to intrinsic reduced expression of EGFR (Figure 5C).

Combination of AG1478 and Crenolanib triggers apoptosis in both GBM CSC pools

The high PDGFR α protein expression reported in all p-CSC of the six cases examined, prompted us to test the pharmacological inhibition of PDGFR α to evaluate its impact on cell growth and survival of CSC. In this study, EGFR signaling inhibition have been shown to be more effective therapeutically than GSI-X, suggesting that the combination with Crenolanib (CR, a selective inhibitor of PDGFR α), would enhance the growth inhibitory effect especially in p-CSC, which were more resistant to treatments. As reported in Figure 6A, B, we observed a significant decrease of cell proliferation in both c-CSC1 and p-CSC1 ($38 \pm 9.5\%$ and $56 \pm 4.4\%$ respectively) with CR (10 μ M) alone after 1 day of treatment by MTS assay, but when used in combination with AG1478 (10 μ M) the average values declined to $24 \pm 9.6\%$ and $34 \pm 9.9\%$ respectively. In addition, Western blots analysis clearly showed an induction of Caspase-3 and PARP-1 cleavage fragments, the effect of which was maximized by combining the two inhibitors (Figure 7A). Of note, is the de-repression of PDGFR α in AG1478-treated CSC1 as well as in p-CSC2 (Figure 7B), this is probably due to a compensatory activation mechanism to evade EGFR TKI. In addition, we detected a downmodulation of PDGFR α expression following Crenolanib treatment, which was a common feature in all cases examined (Figure 7A-C). We applied the same treatments to CSC2 and CSC3 (Figure 6C-F). The MTS assay monitored a significant reduction of cell proliferation to $65 \pm 2.6\%$ and $47 \pm 5\%$ in c-CSC2 and c-CSC3 respectively, while in p-CSC2 and p-CSC3 cell



growth declined to $65 \pm 4.8\%$ and $51 \pm 7.3\%$ respectively with CR alone. Dual treatment was more effective than treatment alone in both CSC2 and CSC3, as reported in Figure 6C-F. Of note, as early as the first day of treatment the two agents exerted a synergistic antiproliferative effect in CSC2 and CSC3 with induction of Caspase-3 and PARP-1 cleavage and reduction of p-Akt1 in CSC3 or Bcl2 in CSC2 (Figure 7B, C).

Modulation of PDGFR α activity regulates cell growth and survival pathways in GBM CSC

To confirm the pivotal role of PDGFR α in cell proliferation, we downregulated his expression by short hairpin RNA mediated-knockdown in p-CSC2. After a brief period of antibiotic selection, either control infect cells (pLKO.1) or two cell clones expressing shPDGFR α were plated for cell growth assessment. shPDGFR α -cells showed a




Figure 5 (See legend on next page.)

(See figure on previous page.)

Figure 5 Cell invasion properties of GBM CSC. (A) In absence of GF p-CSC1 have higher invasive ability than c-CSC1 on matrigel invasion assay. Addition of GF promotes invasiveness of both cell populations of case 1, which is blocked by AG1478. Drugs combination don't improve the effect of monotherapy but induces a strong repression of MMP9 protein expression. The values of MMP9 repression are calculated respect to DMSO-vehicle. (B) In absence of GF, p-CSC2 have higher invasive ability than c-CSC2. Addition of GF promotes the invasiveness of both cell populations of case 2 but only the combination of GSI-X and AG1478 significantly impairs the invasive performance of c-CSC2 and p-CSC2, which correlates to reduction of MMP9 protein. The values of MMP9 repression are calculated respect to DMSO-vehicle. (C) In absence of GF c-CSC3 holds higher invasive ability than p-CSC3 and similarly to other cases the addition of GF favors significantly their invasive features. AG1478 impairs c-CSC3 invasion but not p-CSC3. Moreover, drug combination increases the effect of AG1478 monotherapy only in c-CSC3. This finding correlates to a decline of MMP9 protein expression. Conversely, p-CSC3 shows drug resistance and retains high levels of MMP9. The values of MMP9 repression are calculated respect to DMSO-vehicle. Error bars represent the mean \pm SD (n = 3). All data shown are representative of results obtained from experiments conducted three times.





Figure 6 AG1478 and Crenolanib trigger cell growth inhibition in both c-CSC and p-CSC. (A, B) AG1478 alone or in combination with CR determine a significant antiproliferative effect in c-CSC1 and p-CSC1 either at 1 day or 2 days of treatment. No synergistic antiproliferative effect is monitored with the combination therapy. (C, D) AG1478 alone or in combination with CR determine a significant antiproliferative effect in c-CSC2 and p-CSC2 either at 1 day or 2 days of treatment. The combination therapy triggers a synergistic antiproliferative effect in p-CSC2 at day 1. (E, F) AG1478 and CR provided alone determine a significant antiproliferative effect in c-CSC3 and p-CSC3 either at 1 day or 2 days of treatment. The combination therapy triggers a synergistic antiproliferative effect in both c-CSC3 and p-CSC3 at day 1 of treatment. Error bars represent the mean \pm SD (n = 3). All data shown are representative of results obtained from experiments conducted twice.



significant reduction of cell growth rate compared to pLKO.1 cells, which was consistently maintained up to the seventh day in culture (Figure 7D). In order to evaluate p-CSC response to PDGFAA, c-CSC2 and p-CSC2 were undergone to growth factors (EGF and bFGF) deprivation for 2 days, and then exposed to PDGFAA (40 ng/ml) for short periods of time (Figure 7E). PDGFAA stimulation induced early activation of p-Erk1/2 and p-Akt1 in p-CSC2 within 5 minutes, which declined to basal levels later. Conversely, c-CSC2 displayed a faint response to PDGFAA.

Discussion

In recent years, aberrant RTK expression has gained much attention in cancer stem cells biology. Several TKI and

blocking antibodies anti-EGFR have been tested and others are currently in 30 ongoing clinical studies for GBM treatment, according to the website of *clinicaltrials.gov* (United States National Institutes of Health). Despite the seemingly critical role of EGFR signaling in GBM, only 10 to 20 percent of patients have shown a modest improvement by EGFR kinase inhibitors [30,31]. These initials clinical results have demonstrated the need to understand GBM's resistance mechanisms to EGFR inhibition as well as to other inhibitors in order to develop more effective therapies [32]. A sub-population of CD133 positive cancer stem cells with higher Notch activity has been identified in GBM [33]. Notch inhibition by γ -secretase inhibitors depleted CD133+ glioblastoma cells, making these compounds potential chemotherapeutic agents to target high-

grade gliomas. A terminated phase I pharmacological study with MK-0752 (a gamma-secretase inhibitor developed by Merck), demonstrated clinical benefits in patients with advanced solid tumors, including GBM, and now combination trials are ongoing to maximize the therapeutic benefit with this novel agent [34].

PDGFR α is another critical gene in glioma biology, as it is the second most frequently mutated TRK in GBM, following EGFR. Similar to EGFR, PDGFR α has been shown to be overexpressed, amplified, mutated and rearranged in GBM. PDGFR α gene amplification could be used as a potential prognostic biomarker and therapeutic target in GBM [35]. A phase II study with a monoclonal antibody anti-PDGFR α is under investigation in recurrent GBM.

In the current study we assessed the effects of Notch1, EGFR and PDGFR inhibitors as a means of investigating GBM CSC responses to disruption of specific intracellular signaling relevant to GBM CSC maintenance. We identified, in some cases, a heterogeneous expression of NOTCH1 gene, in particular we reported sustained levels of expression in p-CSC3 and p-CSC4 with respect to relative counterparts c-CSC. In three cases deeply investigated, c-CSC pools were impaired in cell growth by GSI-X, while the relative p-CSC pools resisted treatment or delayed the inhibitory effects. The Notch1 pathway was investigated in more detail in three cases and surprisingly we found that Notch1 target Hes1 protein was not down modulated by Notch inhibition. This finding may be explained by the results of Wall et al. [28], who demonstrated that sonic hedgehog (shh)-driven stabilization of Hes1 was independent of Notch signaling and required the Shh effector Gli2. Moreover, a physiological crosstalk has been provided between Notch-Hes1 and JAK-STAT pathways in the developing central nervous system, as Hes proteins (Hes1 and Hes5) bind to STAT3 directly, thereby suggesting that Hes proteins may function as non-scaffold proteins that allow JAK2 to phosphorylate STAT3 [36]. More recently, other authors report that STAT3 and NF- κ B signaling regulates the Notch pathway in glioblastoma cancer stem cells [37]. It is possible that as a consequence of this complex interactions, Notch pathway would be partially hampered by GSI-X treatment, as we detected uncertain down modulation of the cell cycle progression protein CycD1 in c-CSC2 (but not of p27), and of the anti-apoptotic protein survivin in c-CSC3 (but not of Bcl2). Based on the above results only a small fraction of cell death was monitored in GSI-treated c-CSC.

A study on 196 cases of GBM from the TCGA consortium, reports that the expression of Notch signaling components was enriched in the classical/proliferative GBM subtype characterized by EGFR+/PDGFRA- and in the proneural subtype, characterized by PDGFRA+/IDH1+ [38], indeed we did find these correlations in our GBM

CSC. Accordingly to the literature, fifty percent of GBM CSC examined in the current study had shown overexpression of EGFR, which resulted independently from Notch1 activation, despite other laboratories' reports that Notch and EGFR signaling pathways converge to regulate the same gene targets. Purow et al. [39], report that Notch1 regulates transcription of EGFR through p53 and Xu et al. [40], stated that knockdown of Notch1 expression by siRNA downregulated the expression of EGFR and the important components of its downstream pathways, including PI3K/Akt, K-Ras, Cyclin D1 and MMP9.

The high EGFR expression in GBM CSC prompted us to explore EGFR signaling as a therapeutic approach and afterwards we decided on combinatorial therapy anti-Notch and anti-EGFR. Our and other laboratories have reported that a specific inhibitor for EGFR efficiently blocked EGF-induced activation of MMP9 and reduced cancer invasiveness [40]. The inhibitory effects of AG1478 on CSC invasive ability would impact consequently also STAT3 signaling [41], as reported in the current study except for p-CSC1 and p-CSC3, for whose we did not observed any modulation of phosphorylation on Y705-STAT3 following AG1478 treatment. STAT3 signaling is also involved in GBM invasion promotive effect of IL-6 [42]. The combination of AG1478 and GSI-X exceeded the effects of monotherapy as reported in Western blots, flow cytometry and cell invasion assays. The uncertain effects mediated by Notch inhibition alone were clearly overridden by combining AG1478, which produced: i) apoptosis, ii) switch-off of p-Akt1 and p-Erk1/2 expression, and iii) reduction of CycD1 and Survivin, except in the most resistant p-CSC3 and the arrested CSC1. These effects mirrored a marked reduction of CSC invasive ability with MMP9 protein down modulation as observed in most of the cases except for p-CSC3.

EGFR has been the focus of many brain tumor studies and it is noteworthy that expression of wild-type or constitutively active mutant EGFR is rarely oncogenic as a single lesion, whereas expression of PDGFR ligands can induce tumors as a single driving event [43,18]. PDGFs and PDGFRs deregulated expression are found even in low-grade gliomas [43-45], suggesting that this pathway is possibly an early oncogenic event, in contrast to EGFR which is much more commonly found in high-grade gliomas [46]. Here we report for the first time the inherent overexpression of PDGFR α in GBM p-CSC with respect to c-CSC in all six patient samples examined, suggesting the dominance of its signal in proliferation and maintenance of GBM and in particular of peritumor tissue-derived CSC. Recently, it has been reported that tyrosine-protein phosphatase non-receptor type 11 (SHP-2) and PI3K mediate PDGFR α -promoted glioma tumor growth and invasion [47]. Based on our results and those of other authors, we hypothesize that the combinations of abnormal expression

and activation of growth factor receptors such as: EGFR, PDGFR α , PDGFR β and Notch1 in GBM CSC or -derived cell lines may influence cell response to targeted therapies, thereby limiting the efficacy of single anti-EGFR or anti-PDGFR or anti-Notch1 therapies as we have seen in this study [48,49].

To demonstrate that PDGFR α was relevant to GBM CSC maintenance, we tested a potent PDGFR α signaling inhibitor Crenolanib in the most studied cases (cases 1-3). A significant reduction of cell growth of either c-CSC or p-CSC was reported, with remarkable effects on the 2nd day of treatment on p-CSC3. The combination therapy with AG1478 enhanced apoptosis induced by CR alone, supporting the hypothesis that targeting more RTKs would probably weaken the tumor growth. It is important to note the up regulation of PDGFR α protein observed in some cases in response to EGFR inhibition, which suggests its role in mediating AG1478 resistance in GBM. Recently, it has been reported that this event is emerging as a frequent, non-genetic mechanism of targeted cancer drug resistance, as reported in GBM CSC, colorectal cancer cells and in non-small cell lung cancer [23]. In addition, genetic knockdown of PDGFR α in p-CSC2 caused slow-down of cell growth rate and exogenous PDGFAA stimulation of starved GBM CSC promoted p-Erk1/2 and p-Akt1 activation in p-CSC, confirming the concept that PDGFR α activation provided survival signals in p-CSC vs. c-CSC.

Conclusions

Our results collectively support a key role of EGFR and PDGFR α signaling in survival of Glioblastoma cancer stem cells. PDGFR α was overexpressed in GBM peritumor tissues derived-CSC compared to counterparts GBM c-CSC, indicating this pathway a pivotal therapeutic target in GBM. We also provide the rationale for simultaneous targeting of EGFR and PDGFR, with prospective of an improvement of survival and quality of life of GBM patients.

Material and methods

Ethical statement

Procedures for collection of adult human GBM CSC were approved by the Ethical Committee of the Catholic University of Rome as reported previously [24]. Informed consent was obtained and all patients were fully aware of the aims and scope of this work. The ethical principles of the declaration of Helsinki were strictly followed.

Cell culture and treatment of human Glioblastoma cancer stem cells

We have used the same clinical materials reported in our previous papers [24,25]. In brief, the CSC cells were retrieved from adult patients affected by GBM and undergoing craniotomy at the Institute of Neurosurgery, Catholic University-School of Medicine of Rome, Italy.

Dissociated cells were cultured in the presence of human recombinant EGF (20 ng/ml; PeproTech, Rocky Hill, NJ), human recombinant bFGF (10 ng/ml; PeproTech), in DMEM/F12 (1:1) serum-free medium (Invitrogen, Carlsband, CA) containing L glutamine 2 mM, glucose 0.6%, putrescine 9.6 μ g/ml, progesterone 0.025 mg/ml, sodium selenite 5.2 ng/ml, insulin 0.025 mg/ml, apo-transferrin sodium salt 0.1 mg/ml, sodium bicarbonate 3 mM, Hepes 5 mM, BSA 4 mg/ml, heparin 4 μ g/ml (all purchased by Sigma-Aldrich). Floating neurospheres were dissociated with Accutase at 37°C (Merck-Millipore). In some cases, neurospheres were passaged up to passage P60 and the experiments were performed between P14 and P60. Cell starvation was planned for 2 days in Stem Medium w/o EGF and bFGF. Subsequently, PDGF-AA was added (40 ng/ml, Peprotech) for different time points (5', 10', 30', 120' and 24 hours). Cells treatments were performed with GSI-X (also named L-685,458, Calbiochem), AG1478 (Calbiochem) and Crenolanib (CP-8685596, Selleckchem).

ShRNA, transfection and lentivirus production

The experiments on RNA interference were performed using Mission Lentivirus-based shRNA for PDGFR α (NM_006206-Sigma-Aldrich). We amplified three DNA clones (clones numbers: TRCN0000195132, TRCN0000196272, TRCN0000196928) and pLKO.1-puro, as a control for infection. We selected puromycin resistant p-CSC2 expressing three different shRNA sequences, but only two were able to downmodulate PDGFR α (TRCN0000195132 and TRCN0000196928). Human embryonic kidney (HEK)-293 T cells in log-phase growth were transiently transfected using standard LipofectAmine reagent (Invitrogen), with lentivirus-based shRNA (and with pLKO.1 as control) plus helper plasmids (Invitrogen Packaging Plasmids, Carlsband, CA). Media containing the virions were harvested two days after cell transfection and transferred directly onto p-CSC2. Lentiviral infection was performed in the presence of polybrene solution at 8 μ g/ml (Sigma-Aldrich) and the antibiotic puromycin (Euroclone) was added to the cells at 1 μ g/ml for a week to select CSC expressing shRNA sequences.

Western blots

GBM CSC seeded as single cells (1×10^6 /dish) were left for 1 day in proliferation medium before treating them for 1-2 days with the inhibitors, either singly or in combination. Afterwards, cells were collected and washed with PBS plus proteases inhibitors before protein extraction in 100-200 μ l of lysis buffer (1% NP-40, 0.01% SDS, 20 mM Tris-HCl pH 7.4, 300 mM NaCl, 1 mM EDTA, 1 mM Na₃VO₄ and protease inhibitors cocktail - from Sigma-Aldrich). Then, cells were sonicated with two pulses of 5 sec at 50% of amplitude (Sonics and Materials,

Newtown, CT). Equal amounts (30 µg/lane) of total protein extracts, determined by Bio-Rad protein Assay (Bio-Rad, Munchen, Germany), were loaded on NuPAGEBis-Tris gels (Invitrogen), and transferred on Hybond-P Extra membrane (Amersham Biosciences, GE Healthcare Life Science-Buckinghamshire, UK). Filters were immunoblotted using the following primary antibodies: rabbit anti-NICD1, rabbit anti-HES1, rabbit anti-DLL1, rabbit anti-EGFR, rabbit anti-pY1068-EGFR, rabbit anti-PDGFRα, rabbit anti-PDGFRβ, rabbit anti-T202/Y204-ERK1/2 and anti-ERK1/2, rabbit anti-Y705-STAT3 and rabbit anti-STAT3 and anti-Caspase3, (all purchased from Cell Signaling, MA-USA), mouse anti-S473-AKT1 and rabbit anti-AKT1 (Calbiochem), rabbit anti-BCL2 (Millipore), rabbit anti-survivin and anti-MMP9 (Abcam), rabbit anti-Cyclin D1 and anti-p27 (Santa Cruz-USA), mouse anti-β-actin and anti-GAPDH (SIGMA). After three washing with TBS-Tween buffer, immuno-reactive proteins were detected using rabbit anti-mouse, donkey-anti-rabbit and donkey anti-goat horseradish peroxidase-conjugated secondary antibodies directed to the appropriate primary antibodies (Jackson Immunoresearch Laboratories, West Grove, PA). The proteins were then visualized using the chemiluminescence system (Millipore). Gels and Images acquisition was done by HP Photosmart Essential Ver. 1.12 and Adobe Photoshop CS5 respectively. The densitometric analysis of protein bands normalized against to β-actin protein levels were performed from three independent experiments using the ImageJ software (NIH, USA).

Cell proliferation assays

For cell proliferation assay, neurospheres were dissociated into single cells and 1×10^4 cells/well were plated in triplicate on 60 mm plates. Cells were harvested and counted at different time points (3, 5, 7 days in vitro) in growth medium, considering the starting time as the day after plating. For pharmacological studies we used the CellTiter 96 Aqueous One Solution Reagent (Promega), a cell proliferation colorimetric assay containing a novel tetrazolium compound MTS. Briefly, 2×10^4 cells/well were plated in triplicate for each group on 12-well plates and the drugs or DMSO-vehicle were added the day after plating. Before harvesting cells, they were incubated with 100 µl/ml of MTS at 37°C for approximately 1 hour. The metabolically active cells reduced MTS into a soluble formazan product, whose absorbance was measured at 490 nm in a plate reader (Bio-Rad). These experiments were performed three times and each time in triplicate. The absorbance values of the collected samples were subtracted from the background absorbance of medium-only control and expressed as % of control and calculated as mean average \pm SD ($n = 3$).

RT-PCR and custom RT-PCR array

Total RNA was extracted using Triazol and by RNeasy mini kit (Qiagen, USA). cDNAs were obtained using QuantiTect Reverse Transcription kit (Qiagen, USA). Real time reverse transcriptase PCR (RT-PCR) was carried out in triplicate using SYBR Hi-ROX kit (Bioline, UK). RT-PCR and a custom RT-PCR array (Microfluidic Card, Applied Biosystems, CA) were performed with a 7900HT instrument equipped with SDS2.2 software (Applied Biosystems, CA). The PCR primers used for RT-PCR were the following: (Forward) hTBP: GAACATCATGGATCAGAACAACA, (Reverse) hTBP: ATAGG GATTCCGGGAGTCAT; (Forward) hGAPDHAGCCA CATCGCTCAGACA; (Reverse) hGAPDH: GCCCAA TACGACCAAATCC, as internal controls. (Forward) hEGFRvIII: GGCTCTGGAGGAAAAGAAAGGTAAT; (Reverse) hEGFRvIII: TCCTCCATCTCATAGCTGTCTG; (Forward) hEGFR: GCCTTGACTGAGGAACAGCA; (Reverse) hEGFR: TTTGGGAACGGACTGGTTTA; (Forward) hNOTCH1: CGCACAAGGTGTCTTCCAG; (Reverse) hNOTCH1: CGGCGTGTGAGTTGATGA. Relative levels of expression were obtained by normalization with respect to selected housekeeper genes (GAPDH, TBP) by using the Δ Ct method following manufacturer's guide.

Cell invasion assay

For an invasion assay, 1×10^5 cells were resuspended in 0.3 ml of Stem Medium with inhibitors or DMSO-vehicle and placed in triplicate into the top chamber of matrigel-coated transwell insert (Millipore). The bottom wells contained 0.4 ml of Stem Medium with EGF and bFGF, or without these media as controls for the experiment. After 72 h, cells on the top surface of the filter were removed with a cottonswab. Thereafter, the filters were fixed and stained with crystal violet and subsequently washed to collect the staining solution. OD values, proportional to the number of cells, were measured on a plate reader with a 550 nm filter (Bio-Rad). These experiments were performed three times and each time in triplicate. The absorbance values were calculated as mean \pm SD ($n = 3$). These experiments were repeated three times and each time in triplicate.

FACS analysis

Cells were fixed with 0.5 ml of cold Methanol/Acetone Solution (1:5) and left at 4°C for at least 1 hour, then centrifuged at 950 RPM for 5 minutes. The cell pellet was resuspended in 100 µl of PBS, 375 µl of Rnase A (100 µg/ml) and 25 µl of Propidium Iodide (1 mg/ml). Cells were incubated at room temperature for 15 minutes and left in the dark at 4°C until FACS analysis. Samples were acquired on FACS Calibur (BD Becton Dickinson) at 488 nm. The acquired FACS data were analyzed by ModFit LT software (Verity Software House, Inc.) to

determine the percentage of cells sub G1, G1, S and G2/M phases. These experiments were performed twice for each sample.

Statistical analysis

Statistical analysis was performed with Prism5 (GraphPad) and Microsoft Office Excel 2007. All data shown are representative of results obtained from experiments conducted two or three times as specified in the specific sections. The results were analyzed by either One-way Anova and Newman-Keuls post-tests or Two-way ANOVA and Bonferroni's post tests. Data are expressed as mean \pm standard deviation (SD) and P values ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***) were considered statistically significant. To evaluate the synergistic effect of the combination of two drugs on cell growth we referred to Lama et al. [50].

Additional file

Additional file 1: Figure S1. GSI-X did not modulate survival signals and cell growth of p-CSC3. (A) Increasing concentrations of GSI-X did not affect Erk1/2 and Akt1 phosphorylation. (B) Cell growth of p-CSC3 was not affected by high doses of GSI-X. Values are expressed as mean \pm SD (n = 4). ns denotes not specific bands.

Abbreviations

GBM: Glioblastoma multiforme; c-CSC: core cancer stem cells; p-CSC: peritumor cancer stem cells; GSI-X: Gamma secretase inhibitor-X; NICD1: Notch intracellular domain 1; HES1: Hairy enhancer of split 1; DLL1: Delta like ligand 1; PSEN1: Presenilin 1; RTK: Receptor tyrosine kinase; EGFR: Epidermal growth factor receptor; PDGFR: Platelet derived growth factor receptor; TKI: Tyrosine kinase inhibitor; CR: Crenolanib.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CC contributed to conception, experimental design and execution of MTS assays and Western blots; GM and AM contribute to Grant Development; ALV contributed to isolation of GBM CSC; AM and GM performed acquisition of data (managed patients, provided facilities); EP performed the invasion assay; MZ and PP performed the cell cycle analysis; PC performed the cell proliferation assay; CC and AF performed analysis and interpretation of data; HESM helped to write and revise the draft; CC and AM performed the study supervision. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by awards received from ATENA Onlus Foundation and from Italian Ministry for Education, University and Research (MIUR), FIRB Project RBAP10KJCS.

This work is dedicated to my brother Roberto.

Author details

¹Institute of Translational Pharmacology-CNR, Roma, Italy. ²Department of Cytology and Histology, Mansoura University, Mansoura, Egypt. ³Institute of Cell Biology and Neurobiology, Roma, Italy. ⁴Department of Biotechnologies and Biosciences, University of Milan-Bicocca, Milan, Italy. ⁵Institute of Neurosurgery, Catholic University-School of Medicine, Roma, Italy.

Received: 3 July 2014 Accepted: 27 October 2014

Published: 8 November 2014

References

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: **Malignant glioma: genetics and biology of a grave matter.** *Genes Dev* 2001, **15**:1311–1333.
2. Aster JC, Blacklow SC: **Targeting the Notch pathway: twists and turns on the road to rational therapeutics.** *J Clin Oncol* 2012, **30**(19):2418–2420.
3. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L: **Targeting Notch to target cancer stem cells.** *Clin Cancer Res* 2010, **16**(12):3141–3152. Review.
4. Takebe N, Nguyen D, Yang SX: **Targeting notch signaling pathway in cancer: clinical development advances and challenges.** *Pharmacol Ther* 2014, **141**(2):140–149.
5. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA: **Expression of Notch-1 and its ligands, delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation.** *Cancer Res* 2005, **65**(6):2353–2363.
6. Dufraigne J, Funahashi Y, Kitajewski J: **Notch signaling regulates tumor angiogenesis by diverse mechanisms.** *Oncogene* 2008, **27**(38):5132–5137.
7. Fortini ME: **Gamma-secretase-mediated proteolysis in cell-surface-receptor signaling.** *Nat Rev Mol Cell Biol* 2002, **2**(9):673–684.
8. Ronchini C, Capobianco AJ: **Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic).** *Mol Cell Biol* 2001, **21**(17):5925–5934.
9. Sicinska E, Aifantis I, Le Cam L, Swat W, Borowski C, Yu Q, Ferrando AA, Levin SD, Geng Y, Von Boehmer H, Sicinski P: **Requirement for cyclin D3 in lymphocyte development and T cell leukemias.** *Cancer Cell* 2003, **4**(6):451–461.
10. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsner D, Blacklow SC, Pear WS, Aster JC: **c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.** *Genes Dev* 2006, **20**:2096–2109.
11. Chen Y, Fischer WH, Gill GN: **Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH.** *J Biol Chem* 1997, **272**(22):14110–14114.
12. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E: **Glioblastoma subclasses can be defined by activity among signal transduction pathway and associated genomic alterations.** *PLoS One* 2009, **4**(11):e7752.
13. Le Mercier M, Hastir D, Moles Lopez X, De Neve N, Maris C, Trepant AL, Rorive S, Decaestecker C, Salmon I: **A simplified approach for the molecular classification of Glioblastomas.** *PLoS One* 2012, **7**(9):e45475.
14. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR: **Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.** *Cancer Treat* 2006, **32**:74–89.
15. Gan HK, Kaye AH, Luwor RB: **The EGFRvIII variant in glioblastoma multiforme.** *J Clin Neurosci* 2009, **16**:748–754.
16. Collaborators (231): **The Cancer Genome Atlas project. Comprehensive genomic characterization defines human glioblastoma genes and core pathway.** *Nature* 2008, **455**:1061–1068.
17. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: **A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.** *Proc Natl Acad Sci U S A* 1994, **91**:7727–7731.
18. Dai C, Celestino JC, Okada Y, Luo DN, Fuller GN, Holland EC: **PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.** *Genes Dev* 2001, **15**:1913–1925.
19. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P: **Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.** *J Neurosci* 2006, **26**:6781–6790.
20. Fredriksson L, Li H, Eriksson U: **The PDGF family: four gene products forms five dimeric isoforms.** *Cytokine Growth Factor Rev* 2004, **15**:197–204.
21. Blume-Jensen P, Hunter T: **Oncogenic kinase signalling.** *Nature* 2001, **411**(6835):355–365.
22. Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN: **Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.** *Genes Dev* 2012, **26**(11):1247–1262.

23. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HL, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS: **De-repression of PDGFR β transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.** *Cancer Discov* 2013, **3**(5):534–547.
24. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, DiMeco F, Dalprà L, Vescovi AL: **Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.** *Oncogene* 2009, **28**(15):1807–1811.
25. Mangiola A, Saulnier N, De Bonis P, Orteschi D, Sica G, Lama G, Pettorini BL, Sabatino G, Zollino M, Lauriola L, Colabianchi A, Proietti G, Kovacs G, Maira G, Anile C: **Gene expression profile of Glioblastoma peritumoral tissue: an ex vivo study.** *PLoS One* 2013, **8**(3):e57145.
26. Fortini ME: **Notch signaling: the core pathway and its posttranslational regulation.** *Dev Cell* 2009, **19**:633–647.
27. Wall DS, Mears AJ, McNeill B, Mazerolle C, Thurig S, Wang Y, Kageyama R, Wallace VA: **Progenitor cell proliferation in the retina is dependent on Notch-independent Sonic hedgehog/Hes1 activity.** *J Cell Biol* 2009, **184**(1):101–112.
28. Chen J, Huang Q, Wang F: **Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma.** *Tumour Biol* 2014, Apr 27. (Epub ahead of print).
29. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q, Ge J: **Notch1 promotes glioma cell migration and invasion by stimulating β -catenin and NF- κ B signaling via AKT activation.** *Cancer Sci* 2012, **103**(2):181–190.
30. Vivanco I, Mellinghoff IK: **Epidermal growth factor receptor inhibitors in oncology.** *Curr Opin Oncol* 2010, **22**(6):573–578.
31. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA, Vogelbaum MA, Weil RJ, Elson P, Barnett GH: **Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.** *J Neurooncol* 2010, **98**(1):93–99.
32. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: **Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.** *Mol Cancer* 2006, **5**:67.
33. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkha G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG: **NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.** *Stem Cells* 2010, **28**(1):5–16.
34. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, Butowski N, Groves MD, Kesari S, Freedman SJ, Blackman S, Watters J, Loboda A, Podtelezchnikov A, Lunceford J, Chen C, Giannotti M, Hing J, Beckman R: **Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.** *J Clin Oncol* 2012, **30**(19):2307–2313.
35. Alentorn A, Marie Y, Carpentier C, Boisselier B, Giry M, Labussiere M, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A: **Prevalence, clinico-pathological value, and cooccurrence of PDGFRA abnormalities in diffuse gliomas.** *Neuro Oncol* 2012, **14**(11):1393–1403.
36. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y: **Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling.** *Nat Cell Biol* 2004, **6**(6):547–554.
37. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, Pfeffer LM: **Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κ B signaling in glioblastoma cancer stem cells regulates the Notch pathway.** *J Biol Chem* 2013, **288**(36):26167–26176.
38. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, et al: **Cancer Genome Atlas Research Network: integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.** *Cancer Cell* 2010, **17**(1):98–110.
39. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, Su Q, Kotliarov Y, Lee J, Zhang W, Fine HA: **Notch-1 regulates transcription of the epidermal growth factor receptor through p53.** *Carcinogenesis* 2008, **29**(5):918–925.
40. Xu P, Qiu M, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H, Pu P: **The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo.** *J Neurooncol* 2010, **97**(1):41–51.
41. Ghosh MK, Sharma P, Harbor PC, Rahaman SO, Haque SJ: **PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.** *Oncogene* 2005, **24**(49):7290–7300.
42. Liu Q, Li G, Li R, Shen J, He Q, Deng L, Zhang C, Zhang J: **IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines.** *J Neurooncol* 2010, **100**(2):165–176.
43. Uhrbom L, Hesselager G, Nister M, Westermark B: **Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus.** *Cancer Res* 1998, **58**:5275–5279.
44. Maxwell M, Naber SP, Wolfe HJ, Galanopoulos T, Hedley-Whyte ET, Black PM, Antoniadou HN: **Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.** *J Clin Invest* 1990, **86**:131–140.
45. Plate KH, Breier G, Farrell CL, Risau W: **Platelet-derived growth factor receptor-b is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.** *Lab Invest* 1992, **67**:529–534.
46. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, Depinho RA, Cavenee WK: **Malignant astrocytic glioma: genetics, biology, and paths to treatment.** *Genes Dev* 2007, **21**:2683–2710.
47. Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA, Johnson GR, Hu B, Cheng SY: **Dynamin 2 mediates PDGFR α -SHP-2-promoted glioblastoma growth and invasion.** *Oncogene* 2012, **31**(21):2691–2702.
48. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW: **Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.** *Proc Natl Acad Sci U S A* 2012, **109**(8):3041–3046.
49. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, Depinho RA: **Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.** *Science* 2007, **318**(5848):287–290.
50. Lama G, Angelucci C, Recchia F, Sica G: **Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells.** *Cancer Lett* 1996, **100**(1–2):181–189. Erratum in: *Cancer Lett* 1996, **103**(2): 243.

doi:10.1186/1476-4598-13-247

Cite this article as: Cenciarelli et al.: PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment. *Molecular Cancer* 2014 **13**:247.

Submit your next manuscript to BioMed Central and take full advantage of:

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

